{"entity":{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","aka":[],"tldr":"A phase 1/2 trial of Golidocitinib in peripheral T-cell lymphomas, run by Dizal Pharmaceuticals, now recruiting.","summary":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) is a phase 1/2 interventional study registered as NCT07496229 by Dizal Pharmaceuticals, with 165 participants planned, started 2026-04-15 and due to reach its primary completion in 2029-09. Interventions recorded: GW5282 combined with Golidocitinib and Conventional CHOP regimen.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07496229","url":"https://clinicaltrials.gov/study/NCT07496229"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["golidocitinib"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07496229","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Efficacy and Safety of GW5282 in Combination With Golidocitinib in the Treatment of T-Cell Lymphoma","sponsor":"Dizal Pharmaceuticals","enrolled":165,"outcomes":[]},"route":"/trials/nct07496229/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}